
<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
        <link rel="canonical" href="http://spbm.ohio.gainwelltechnologies.com/UPDL%20and%20Supporting%20Documents/Supporting%20Documents/UPDL_criteria/">
      
      
        <link rel="prev" href="../">
      
      
        <link rel="next" href="../additional_therapeutic/">
      
      
      <link rel="icon" href="../../../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.6.1, mkdocs-material-9.5.36">
    
    
      
        <title>UPDL Criteria - Ohio SPBM Demo</title>
      
    
    
      <link rel="stylesheet" href="../../../assets/stylesheets/main.06209087.min.css">
      
        
        <link rel="stylesheet" href="../../../assets/stylesheets/palette.06af60db.min.css">
      
      


    
    
      
    
    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
    <script>__md_scope=new URL("../../..",location),__md_hash=e=>[...e].reduce(((e,_)=>(e<<5)-e+_.charCodeAt(0)),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="gainwell" data-md-color-primary="indigo" data-md-color-accent="indigo">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
        
        <a href="#updl_criteria" class="md-skip">
          Skip to content
        </a>
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href="../../.." title="Ohio SPBM Demo" class="md-header__button md-logo" aria-label="Ohio SPBM Demo" data-md-component="logo">
      
  <img src="../../../img/favicon.ico" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3zm0 5h18v2H3zm0 5h18v2H3z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Ohio SPBM Demo
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              UPDL Criteria
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="(prefers-color-scheme: light)" data-md-color-scheme="gainwell" data-md-color-primary="indigo" data-md-color-accent="indigo"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6m0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4M7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="(prefers-color-scheme: dark)" data-md-color-scheme="slate" data-md-color-primary="indigo" data-md-color-accent="indigo"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var palette=__md_get("__palette");if(palette&&palette.color){if("(prefers-color-scheme)"===palette.color.media){var media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']");palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent")}for(var[key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.52 6.52 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.52 6.52 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" tabindex="0" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/gainwell-ohio/spbm/" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--! Font Awesome Free 6.6.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2024 Fonticons, Inc.--><path d="M439.55 236.05 244 40.45a28.87 28.87 0 0 0-40.81 0l-40.66 40.63 51.52 51.52c27.06-9.14 52.68 16.77 43.39 43.68l49.66 49.66c34.23-11.8 61.18 31 35.47 56.69-26.49 26.49-70.21-2.87-56-37.34L240.22 199v121.85c25.3 12.54 22.26 41.85 9.08 55a34.34 34.34 0 0 1-48.55 0c-17.57-17.6-11.07-46.91 11.25-56v-123c-20.8-8.51-24.6-30.74-18.64-45L142.57 101 8.45 235.14a28.86 28.86 0 0 0 0 40.81l195.61 195.6a28.86 28.86 0 0 0 40.8 0l194.69-194.69a28.86 28.86 0 0 0 0-40.81"/></svg>
  </div>
  <div class="md-source__repository">
    Evergreen
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
            
<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-grid">
    <ul class="md-tabs__list">
      
        
  
  
  
    <li class="md-tabs__item">
      <a href="../../.." class="md-tabs__link">
        
  
    
  
  Welcome

      </a>
    </li>
  

      
        
  
  
  
    
    
      <li class="md-tabs__item">
        <a href="../../../Clinical%20and%20Technical%20Reference%20Guide/peer_to_peer/" class="md-tabs__link">
          
  
  Clinical and Technical Reference Guide

        </a>
      </li>
    
  

      
        
  
  
  
    
    
      <li class="md-tabs__item">
        <a href="../../../Forms/decision_tree_forms/" class="md-tabs__link">
          
  
  Forms

        </a>
      </li>
    
  

      
        
  
  
  
    
    
      <li class="md-tabs__item">
        <a href="../../../Learning%20Materials/Access_and_Maintenance/" class="md-tabs__link">
          
  
  Learning Materials

        </a>
      </li>
    
  

      
        
  
  
  
    
    
      <li class="md-tabs__item">
        <a href="../../../Pharmacist%20Reference%20Guide/Links/" class="md-tabs__link">
          
  
  Pharmacist Reference Guide

        </a>
      </li>
    
  

      
        
  
  
    
  
  
    
    
      <li class="md-tabs__item md-tabs__item--active">
        <a href="../../medical_necessity_policy/" class="md-tabs__link">
          
  
  UPDL and Supporting Documents

        </a>
      </li>
    
  

      
        
  
  
  
    
    
      <li class="md-tabs__item">
        <a href="../../../Work%20Manager%20Resources/communication_strategies/" class="md-tabs__link">
          
  
  Work Manager Resources

        </a>
      </li>
    
  

      
        
  
  
  
    
    
      <li class="md-tabs__item">
        <a href="../../../about/About/" class="md-tabs__link">
          
  
  About

        </a>
      </li>
    
  

      
    </ul>
  </div>
</nav>
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


  


<nav class="md-nav md-nav--primary md-nav--lifted" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href="../../.." title="Ohio SPBM Demo" class="md-nav__button md-logo" aria-label="Ohio SPBM Demo" data-md-component="logo">
      
  <img src="../../../img/favicon.ico" alt="logo">

    </a>
    Ohio SPBM Demo
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/gainwell-ohio/spbm/" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--! Font Awesome Free 6.6.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2024 Fonticons, Inc.--><path d="M439.55 236.05 244 40.45a28.87 28.87 0 0 0-40.81 0l-40.66 40.63 51.52 51.52c27.06-9.14 52.68 16.77 43.39 43.68l49.66 49.66c34.23-11.8 61.18 31 35.47 56.69-26.49 26.49-70.21-2.87-56-37.34L240.22 199v121.85c25.3 12.54 22.26 41.85 9.08 55a34.34 34.34 0 0 1-48.55 0c-17.57-17.6-11.07-46.91 11.25-56v-123c-20.8-8.51-24.6-30.74-18.64-45L142.57 101 8.45 235.14a28.86 28.86 0 0 0 0 40.81l195.61 195.6a28.86 28.86 0 0 0 40.8 0l194.69-194.69a28.86 28.86 0 0 0 0-40.81"/></svg>
  </div>
  <div class="md-source__repository">
    Evergreen
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../../.." class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Welcome
  </span>
  

      </a>
    </li>
  

    
      
      
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../../Clinical%20and%20Technical%20Reference%20Guide/peer_to_peer/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    Clinical and Technical Reference Guide
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

    
      
      
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../../Forms/decision_tree_forms/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    Forms
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

    
      
      
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../../Learning%20Materials/Access_and_Maintenance/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    Learning Materials
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

    
      
      
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../../Pharmacist%20Reference%20Guide/Links/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    Pharmacist Reference Guide
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

    
      
      
  
  
    
  
  
  
    
    
    
      
        
        
      
      
    
    
      
    
    <li class="md-nav__item md-nav__item--active md-nav__item--section md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_6" checked>
        
          
          <label class="md-nav__link" for="__nav_6" id="__nav_6_label" tabindex="">
            
  
  <span class="md-ellipsis">
    UPDL and Supporting Documents
  </span>
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_6_label" aria-expanded="true">
          <label class="md-nav__title" for="__nav_6">
            <span class="md-nav__icon md-icon"></span>
            UPDL and Supporting Documents
          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../medical_necessity_policy/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Medical Necessity Policy and Procedures
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../otc_list/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    OTC List
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../Analgesic_Agents/NSAIDs/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    Analgesic Agents
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../BloodFCT_Agents/colony_stimulating_factors/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    BloodFCT Agents
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../CNS_Agents/alzheimers_agents/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    CNS Agents
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../Cardio_Agents/angina_hypertension/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    Cardio Agents
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../Derma_Agents/oral_acne_products/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    Derma Agents
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../Endocrine_Agents/androgens/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    Endocrine Agents
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../Gastro_Agents/anti-emetics/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    Gastro Agents
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../Genitourinary_Agents/benign_prostatic_hyperplasia/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    Genitourinary Agents
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../Immuno_Agents/systematic_inflammatory/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    Immuno Agents
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../Infectious_Disease_Agents/antifungals/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    Infectious Disease Agents
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../Ophthalmic_Agents/NSAIDs/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    Ophthalmic Agents
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../Otic_Agents/antibacterial/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    Otic Agents
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../Respiratory_Agents/antihistamines/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    Respiratory Agents
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

              
            
              
                
  
  
    
  
  
  
    
    
    
      
      
    
    
      
    
    <li class="md-nav__item md-nav__item--active md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_6_16" checked>
        
          
          <label class="md-nav__link" for="__nav_6_16" id="__nav_6_16_label" tabindex="0">
            
  
  <span class="md-ellipsis">
    Supporting Documents
  </span>
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_6_16_label" aria-expanded="true">
          <label class="md-nav__title" for="__nav_6_16">
            <span class="md-nav__icon md-icon"></span>
            Supporting Documents
          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Index
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
        
      
      
        <label class="md-nav__link md-nav__link--active" for="__toc">
          
  
  <span class="md-ellipsis">
    UPDL Criteria
  </span>
  

          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  <span class="md-ellipsis">
    UPDL Criteria
  </span>
  

      </a>
      
        

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
    
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#analgesic_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Analgesic Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#blood_formation_coagulation_and_thrombosis_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Blood Formation, Coagulation, and Thrombosis Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#cardiovascular_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Cardiovascular Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#central_nervous_system_cns_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Central Nervous System (CNS) Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#dermatologic_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Dermatologic Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#endocrine_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Endocrine Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#gastrointestinal_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Gastrointestinal Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#genitourinary_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Genitourinary Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#immunomodulator_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Immunomodulator Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#infectious_disease_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Infectious Disease Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#ophthalmic_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Ophthalmic Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#otic_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Otic Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#respiratory_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Respiratory Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#topical_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Topical Agents
    </span>
  </a>
  
    <nav class="md-nav" aria-label="Topical Agents">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#non-preferred" class="md-nav__link">
    <span class="md-ellipsis">
      Non-Preferred
    </span>
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
    </ul>
  
</nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../additional_therapeutic/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Additional Therapeutic Classes with Clinical Criteria
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../payable_active_ingredients/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Payable Active Pharmaceutical Compounding Ingredients and Excipients
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../preferred_drug_list/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Preferred Drug List
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../quantity/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Quantity Limit List
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../specialty_drug_list/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Specialty Drug List by Therapeutic Class
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../supply_list/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Supply list
  </span>
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../Topical_Agents/antifungal/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    Topical Agents
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../ePA%20Question%20Sets/BloodBlood%20Products%20Hematopoietic%20Agents/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    ePA Question Sets
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
      
      
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../../Work%20Manager%20Resources/communication_strategies/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    Work Manager Resources
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

    
      
      
  
  
  
  
    
    
    
      
      
    
    
      
        
        
      
    
    <li class="md-nav__item md-nav__item--pruned md-nav__item--nested">
      
        
  
  
    <a href="../../../about/About/" class="md-nav__link">
      
  
  <span class="md-ellipsis">
    About
  </span>
  

      
        <span class="md-nav__icon md-icon"></span>
      
    </a>
  

      
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
    
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#analgesic_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Analgesic Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#blood_formation_coagulation_and_thrombosis_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Blood Formation, Coagulation, and Thrombosis Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#cardiovascular_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Cardiovascular Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#central_nervous_system_cns_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Central Nervous System (CNS) Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#dermatologic_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Dermatologic Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#endocrine_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Endocrine Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#gastrointestinal_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Gastrointestinal Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#genitourinary_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Genitourinary Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#immunomodulator_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Immunomodulator Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#infectious_disease_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Infectious Disease Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#ophthalmic_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Ophthalmic Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#otic_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Otic Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#respiratory_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Respiratory Agents
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#topical_agents" class="md-nav__link">
    <span class="md-ellipsis">
      Topical Agents
    </span>
  </a>
  
    <nav class="md-nav" aria-label="Topical Agents">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#non-preferred" class="md-nav__link">
    <span class="md-ellipsis">
      Non-Preferred
    </span>
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
    </ul>
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              <article class="md-content__inner md-typeset">
                
                  

  
    <a href="https://github.com/gainwell-ohio/spbm/edit/main/docs/UPDL and Supporting Documents/Supporting Documents/UPDL_criteria.md" title="Edit this page" class="md-content__button md-icon">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20.71 7.04c.39-.39.39-1.04 0-1.41l-2.34-2.34c-.37-.39-1.02-.39-1.41 0l-1.84 1.83 3.75 3.75M3 17.25V21h3.75L17.81 9.93l-3.75-3.75z"/></svg>
    </a>
  
  


<h1 id="updl_criteria">UPDL Criteria<a class="headerlink" href="#updl_criteria" title="Permanent link">&para;</a></h1>
<p><a href="https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20criteria%20effective%2001.01.2024.pdf#overlay-context=drug-coverage">UPDL Criteria</a></p>
<h2 id="analgesic_agents">Analgesic Agents<a class="headerlink" href="#analgesic_agents" title="Permanent link">&para;</a></h2>
<p>Analgesic Agents: <strong>Gout</strong></p>
<p><strong>Length of Authorizations:</strong> 365 days except 180 days for Familial Mediterranean Fever</p>
<p><strong>All Authorizations:</strong> Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Clinical PA Criteria:</strong></p>
<ul>
<li>Must have had an inadequate clinical response with an NSAID and oral corticosteroid within the last 30 days for acute gout diagnosis <strong>OR</strong></li>
<li>Must have had an inadequate clinical response of at least 30 days with the maximally tolerated xanthine oxidase inhibitor dose for chronic gout diagnosis</li>
</ul>
<p><strong>Non-Preferred Criteria:</strong></p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Colchicine Capsule (Mitigare) Criteria:</strong></p>
<ul>
<li>Must have had an inadequate clinical response of 30 days with colchicine tablets</li>
</ul>
<p><strong>Additional Colchicine Solution (Gloperba) Criteria:</strong></p>
<ul>
<li>Must be unable to swallow tablets or capsules for authorization of colchicine solution</li>
</ul>
<p><strong>Subsequent Authorization Criteria:</strong></p>
<ul>
<li>Must provide documentation of patient’s clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>QL</strong> – All colchicine products: 6 doses per claim for acute gout; 2 doses per day for 30 days for chronic gout; 4 doses per day per 30 days for Familial Mediterranean Fever</p>
<p>Analgesic Agents: <strong>NSAIDS</strong></p>
<p><strong>Length of Authorizations</strong>: Dependent upon the table below</p>
<table>
<thead>
<tr>
<th style="text-align: center;"></th>
<th style="text-align: center;">Authorization Length</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align: center;">H. Pylori Treatment</td>
<td style="text-align: center;">30 days</td>
</tr>
<tr>
<td style="text-align: center;">Transdermal/Topical</td>
<td style="text-align: center;">90 days</td>
</tr>
<tr>
<td style="text-align: center;">All Other Treatments</td>
<td style="text-align: center;">365 days</td>
</tr>
</tbody>
</table>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non- Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong> <ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drugs <ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available) </li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available) </li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>AR</strong> - Naproxen Suspension: a PA is required for patients 12 years and older</p>
<p>Analgesic Agents: <strong>Opioids</strong></p>
<p><strong>Ohio law requires prescribers to request and review an OARRS report before initially prescribing or personally furnishing any controlled substance, such as an opioid analgesic or a benzodiazepine, and gabapentin</strong></p>
<p><strong>Length of Authorizations</strong>: For the course of therapy, up to 180 days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Buprenorphine Topical (Butrans) Criteria</strong>:</p>
<ul>
<li>Must provide documentation of an inadequate clinical response of at least <strong>60 consecutive days</strong> with at least <strong>one</strong> immediate release opioid formulation</li>
<li>Must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
<p><strong>Morphine Sulfate ER (Kadian, MS Contin) &amp; Tapentadol ER (Nucynta) Criteria</strong>:</p>
<ul>
<li>Must provide documentation of an inadequate clinical response of at least <strong>60 consecutive days</strong> with at least <strong>one</strong> immediate release opioid formulation</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>7 days</strong> of at least <strong>two unrelated</strong> preferred drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional SHORT-ACTING Opioids Criteria</strong>:</p>
<ul>
<li>The system defines an “initial request” as having no opioid claims in the previous 90 days</li>
<li><strong>Initial short-acting requests</strong> can be authorized up to 90 days<ul>
<li>Length of authorization is dependent on indication, previous patient utilization, and requested length of therapy (could be more restrictive)</li>
<li>To exceed acute opioid limits, documentation of the following must be provided:<ul>
<li>Diagnosis code which must be for somatic type pain</li>
<li>Prescriber attestation that the benefits and risks of opioid therapy has been discussed with patient</li>
</ul>
</li>
<li>Exemptions to the additional criteria:<ul>
<li>Patients receiving short-acting opioids for active cancer treatment, palliative care, and end-of-life/hospice care, sickle cell, severe burn, traumatic crushing of tissue, amputation, major orthopedic surgery</li>
<li>Prescriber attestation that patient is not opioid naïve (i.e., new to Medicaid or was on higher dose in hospital)</li>
</ul>
</li>
</ul>
</li>
<li><strong>Subsequent short-acting requests</strong> can be authorized up to 180 days<ul>
<li>Documentation of the following must be provided:<ul>
<li>Current treatment plan</li>
<li>Demonstrated adherence to treatment plan through progress notes, including pain and function scores, random urine screenings results reviewed, concerns addressed, and no serious adverse outcomes observed</li>
</ul>
</li>
</ul>
</li>
<li><strong>Dose escalation requests</strong> can be authorized up to 180 days<ul>
<li>Documentation of the following must be provided:<ul>
<li>Prescriber attestation that dose escalation is likely to result in improved function and pain control</li>
<li>Requests for a cumulative daily dose &gt;100 MED must be prescribed by or in consultation with a pain specialist or anesthesiologist consultation</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Effective July 1, 2018, patients with short acting opioid therapy will be limited to 30 MED per day and a maximum of 7 days per prescription. Prior authorization will be required to exceed these limits.</p>
<p><strong>Additional LONG-ACTING Opioids Criteria</strong>:</p>
<ul>
<li>The system defines an "inital request" as having no opioid claims in the previous 90 days</li>
<li><strong>Initial long-acting requests</strong> can be authorized up to 90 days<ul>
<li>Documentation of the following must be provided:<ul>
<li>Request is a daily dose equivalent of ≤ 80 MED</li>
<li>Inadequate clinical response to both non-opioid pharmacologic and non-pharmacologic treatments</li>
<li>History of short-acting opioids for ≥ 60 days</li>
<li>Treatment plan including risk assessment, substance abuse history, concurrent therapies, and requirements for random urine screenings (baseline urine drug tests must be submitted)</li>
<li>Pain and function scores at each visit</li>
<li>Opioid contract required to be in place and submitted with PA form</li>
</ul>
</li>
<li>Exemptions to the additional criteria:<ul>
<li>Patients receiving long-acting opioids for catastrophic injury or cancer pain</li>
</ul>
</li>
</ul>
</li>
<li><strong>Subsequent long-acting requests</strong> can be authorized up to 180 days<ul>
<li>Documentation of the following must be provided:<ul>
<li>Current treatment plan</li>
<li>Demonstrated adherence to treatment plan through progress notes, including pain and function scores, random urine screenings results reviewed, concerns addressed, and no serious adverse outcomes observed</li>
</ul>
</li>
</ul>
</li>
<li><strong>Dose escalation requests</strong> can be authorized up to 180 days<ul>
<li>Documentation of the following must be provided:<ul>
<li>Prescriber attestation that dose escalation is likely to result in improved function and pain control</li>
<li>Requests for a daily dose &gt;100 MED must be prescribed by pain specialist or anesthesiologist consultation</li>
</ul>
</li>
</ul>
</li>
</ul>
<p><strong>Additional Transmucosal Fentanyl Criteria</strong>:</p>
<ul>
<li>Must be prescribed by an oncologist, pain specialist, or hospice/palliative prescriber</li>
<li>Must be concurrently taking a long-acting opioid at a therapeutic dose of any of the following for at least <strong>7 days</strong> without adequate pain relief:</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 60 mg oral morphine/day</td>
<td>≥ 8 mg oral hydromorphone/day</td>
</tr>
<tr>
<td>≥ 25 mcg/hr transdermal fentanyl</td>
<td>≥ 25 mg oral oxymorphone/day</td>
</tr>
<tr>
<td>≥ 30 mg oral oxycodone/day</td>
<td>Equianalgesic dose of another opioid</td>
</tr>
</tbody>
</table>
<p><strong>QL</strong> – Transmucosal Fentanyl: 4 doses per day</p>
<h2 id="blood_formation_coagulation_and_thrombosis_agents">Blood Formation, Coagulation, and Thrombosis Agents<a class="headerlink" href="#blood_formation_coagulation_and_thrombosis_agents" title="Permanent link">&para;</a></h2>
<p>Blood Formation, Coagulation, and Thrombosis Agents: <strong>Colony Stimulating Factors</strong></p>
<p><strong>Length of Authorizations</strong>: Dependent upon diagnosis below</p>
<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Approval Length</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute Myeloid Leukemia (AML)</td>
<td>14 days or duration of chemotherapy regimen</td>
</tr>
<tr>
<td>Malignancy at risk for febrile neutropenia or undergoing myeloablative chemotherapy prior to allogeneic or autologous bone marrow transplantation</td>
<td>14 days or duration of chemotherapy regimen</td>
</tr>
<tr>
<td>Myeloid Engraftment for bone marrow transplant (BMT)</td>
<td>30 days</td>
</tr>
<tr>
<td>Severe, chronic neutropenia with absolute neutrophil count (ANC) of less than 500/mm3 and have symptoms associated with neutropenia (e.g. fever, infections, oropharyngeal ulcers).</td>
<td>30 days</td>
</tr>
<tr>
<td>Hematopoietic radiation injury syndrome</td>
<td>30 days</td>
</tr>
</tbody>
</table>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient’s clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Blood Formation, Coagulation, and Thrombosis Agents: <strong>Hematopoietic Agents</strong></p>
<p><strong>Length of Authorizations</strong>: Dependent upon diagnosis below</p>
<p><strong>Authorization of epoetin alfa or darbepoetin</strong>:
| Diagnosis                                                    | Hemoglobin Level | Approval Length |
| ------------------------------------------------------------ | ---------------- | --------------- |
| Anemia due to chronic renal failure, patient on dialysis     | \&lt;=11            | 365 days        |
| Anemia due to chronic renal failure, patient not on dialysis | \&lt;=10            | 365 days        |
| Chemotherapy-induced anemia                                  | \&lt;=10            | 90 days         |
| Anemia in myelodysplastic syndrome                           | \&lt;=11            | 180 days        |</p>
<p><strong>Approval of epoetin alfa only</strong>:
| Diagnosis                                                                           | Hemoglobin Level | Approval Length |
| ----------------------------------------------------------------------------------- | ---------------- | --------------- |
| Autologous blood donation, patient will require blood transfusions                  | &gt;10, \&lt;=13      | 30 days         |
| Anemia of prematurity, age \&lt;=6 months                                              | N/A              | 42 days         |
| Anemia associated with chronic inflammatory disorders (e.g., rheumatoid arthritis)  | \&lt;=11            | 180 days        |
| Anemia associated with ribavirin combination therapy in hepatitis Cinfected patient | \&lt;=11            | 180 days        |
| Anemia in zidovudine-treated HIV-infected patients                                  | \&lt;=11            | 180 days        |</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong></p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong></li>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage
formulation</li>
<li>Must have had an inadequate clinical response of at least 14 days with at least one preferred drug</li>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong></p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Blood Formation, Coagulation, and Thrombosis Agents: <strong>Hemophilia Factors</strong>*</p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>Grandfathering</strong>*:</p>
<p>Patients who have a claim for a non-preferred drug in the previous 120 days will be automatically approved to continue the. Patients who have taken the drug previously but do not have claims history (e.g. new to Medicaid), will need to submit a prior authorization in order to continue coverage.</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Clinical PA Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's body weight</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Extended Half-Life Factor Criteria</strong>:</p>
<ul>
<li>Must provide attestation that the patient is not a suitable candidate for treatment with a shorter-acting half-life drug</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong></p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Blood Formation, Coagulation, and Thrombosis Agents: <strong>Heparin-Related Preparations</strong></p>
<p><strong>Length of Authorizations</strong>: Dependent upon criteria below</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>For most indications: Guidelines from the American College of Chest Physicians limit duration of therapy in the outpatient setting for most indications to less than 35 days and patients should be transitioned to oral warfarin as soon as possible</li>
<li>For requests over 35 days and/or the patient cannot be transitioned to warfarin, prescriber must submit additional documentation for reasoning:<ul>
<li>For patients with cancer – authorized up to 180 days</li>
<li>For pregnant women – authorized up to 280 days</li>
<li>For patients unable to take warfarin – authorized up to 180 days</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Blood Formation, Coagulation, and Thrombosis Agents: <strong>Oral Anticoagulants</strong></p>
<p><strong>Length of Authorizations</strong>: 365 days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Blood Formation, Coagulation, and Thrombosis Agents: <strong>Oral Antiplatelet</strong></p>
<p><strong>Length of Authorizations</strong>: 365 days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<h2 id="cardiovascular_agents">Cardiovascular Agents<a class="headerlink" href="#cardiovascular_agents" title="Permanent link">&para;</a></h2>
<p>Cardiovascular Agents: <strong>Angina, Hypertension &amp; Heart Failure</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days except nimodipine: 21 days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Propranol Oral Solution (Hemangeol) Criteria</strong>:</p>
<ul>
<li>Must provide documentation of the patient's weight</li>
</ul>
<p><strong>Sacubitril / Valsartan (Entresto) Criteria</strong>:</p>
<ul>
<li>
<p>Must provie documentation of chronic heart failure classified as either NYHA Class II-IV or ACC / AHA Stage B-D
**
Non-Preferred Criteria**:</p>
</li>
<li>
<p>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong></p>
<ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drugs <strong>within the same class</strong>, if indicated for diagnosis<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Finerenone (Kerendia) Criteria</strong>:</p>
<ul>
<li>Must be on a maximally tolerated dose of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker</li>
<li>Must provide documentation of an inadequate clinical response to a SGLT2 Inhibitor <strong>OR</strong> provide documentation of medical necessity beyond convenience for why the patient cannot try a SGLT2 inhibitor (i.e., chronic kidney disease diagnosis)</li>
</ul>
<p><strong>Additional Mavacamten (Camzyos) Criteria</strong>:</p>
<ul>
<li>Must be prescribed by or in consultation with a cardiologist</li>
<li>Must provide documentation of NYHA Class II-III symptoms and left ventricular ejection fraction ≥55%</li>
</ul>
<p><strong>Additional Vericiguat (Verquvo) Criteria</strong>:</p>
<ul>
<li>Must provide documentation of ejection fraction</li>
<li>Must have been hospitalized for the treatment of heart failure in the previous 180 days or needs treatment with an outpatient intravenous diuretic in the previous 90 days</li>
<li>Must be treated with an agent from <strong>All</strong> the following unless contraindicated:<ul>
<li>Angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, <strong>OR</strong> an angiotensin receptor neprilysin inhibitor</li>
<li>Beta-blocker</li>
<li>Aldosterone antagonist and/or SGLT2 inhibitor as appropriate for renal function</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>AR</strong> - Sotylize Solution: a PA is required for patients 6 years and older</p>
<p>Cardiovascular Agents: <strong>Antiarrhythmics</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> (or <strong>90 days</strong> for fibrates) with at least <strong>one preferred</strong> drug in the same drug class<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Cardiovascular Agents: <strong>Lipotropics</strong></p>
<p><strong>Length of Authorizations</strong>: See below</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Juxtapid (Initial)</td>
<td>180 days</td>
</tr>
<tr>
<td>Vascepa, Lovaza, ACL inhibitors (Initial)</td>
<td>84 days</td>
</tr>
<tr>
<td>All others (Initial and Subsequent)</td>
<td>365 days</td>
</tr>
</tbody>
</table>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Clinical PA Criteria</strong>:</p>
<ul>
<li>Must provide documentation of baseline labs <strong>AND</strong> have documented adherence to <strong>90 days</strong> of prescribed lipid lowering medications</li>
<li>Must have had an inadequate clinical response of at least <strong>90 days AND</strong> unable to reach goal LDL-C (see below) despite treatment with maximally tolerated dose of highpotency statin and ezetimibe (or a clinical reason that these drugs cannot be utilized)</li>
</ul>
<p><strong>Non-Preferred Criteria</strong></p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Lovastatin ER (Altoprev), Pitavastatin (Livalo), Fluvastatin (Lescol) Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with <strong>two preferred</strong> drugs in the same drug class</li>
</ul>
<p><strong>Additional Colesevelam (Welchol) Criteria</strong>:</p>
<ul>
<li>Must provide documentation of a Type 2 Diabetes diagnosis</li>
</ul>
<p><strong>Additional Icosapent Ethyl (Vascepa) Criteria</strong>:</p>
<ul>
<li>Must provide documentation of baseline labs indicating triglyceride levels ≥500mg/dL after an inadequate clinical response to fibrates, niacin, and diet/exercise</li>
<li>Must provide documentation of discontinuation of drugs known to increase triglyceride levels (i.e., beta blockers, thiazides, and estrogens), if clinically appropriate</li>
</ul>
<p><strong>Additional Lomitapide (Juxtapid) &amp; ATP Citrate Lysase (ACL) Inhibitor Criteria</strong>:</p>
<ul>
<li>Must provide documentation of baseline labs <strong>AND</strong> have documented adherence to <strong>90 days</strong> of prescribed lipid lowering medications</li>
<li>Must have had inadequate clinical response of at least <strong>90 days AND</strong> unable to reach goal LDL-C with high-potency statin, ezetimibe and PCSK9 inhibitor (or a clinical reason that these drugs cannot be utilized)</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>High potency statins: atorvastatin (Lipitor) 40-80mg &amp; rosuvastatin (Crestor) 20-40mg</li>
<li>LDL goals for <strong>Familial Hypercholesterolemia</strong> (includes Heterozygous &amp; Homozygous FH): LDL ≤ 100mg/dL for adults or LDL ≤ 110mg/dL for those &lt; 18 years of age</li>
<li>LDL goals for <strong>Clinical Atherosclerotic Cardiovascular Disease (ASCVD)</strong>: LDL ≤ 70mg/dL</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Cardiovascular Agents: <strong>Pulmonary Arterial Hypertension</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>Grandfathering</strong>:</p>
<p>Patients who have a claim for a non-preferred drug in the previous 120 days will be automatically approved to continue the drug. Patients who have taken the drug previously but do not have claims history (e.g. new to Medicaid), will need to submit a prior authorization in order to continue coverage.</p>
<p><strong>All Authorizations</strong>: Must be precribed in accordance with FDA approved labeling</p>
<p><strong>Clinical PA Criteria</strong></p>
<p>Must provide documentation of NYHA Functional Class for Pulmonary Hypertension and symptoms experienced by patient</p>
<p><strong>Non-Preferred Criteria</strong></p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drugs, <strong>one</strong> of which must be a phosphodiesterase-5 inhibitor<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>Patients who have class III or IV symptoms defined by the NYHA Functional Class for Pulmonary Hypertension may be authorized for inhalation or intravenous agents</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong></p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>AR</strong> - Sildenafil Oral Solution: a PA is required for patients 6 years and older</p>
<h2 id="central_nervous_system_cns_agents">Central Nervous System (CNS) Agents<a class="headerlink" href="#central_nervous_system_cns_agents" title="Permanent link">&para;</a></h2>
<p>Central Nervous System Agents: <strong>Alzheimer's Agents</strong>*</p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>Grandfathering</strong>:</p>
<p>Patients who have a claim for a non-preferred drug in the previous 120 days will be automatically approved to continue the drug. Patients who have taken the drug previously but do not have claims history (e.g. new to Medicaid), will need to submit a prior authorization in order to continue coverage.</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>AR</strong> - All drugs: a PA is required for patients younger than 40 years</p>
<p>Central Nervous Syster Agents: <strong>Anti-Migraine Agents, Acute</strong></p>
<p><strong>Length of Authorizations</strong>: 180 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Step Therapy Approval Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> with at least <strong>two preferred</strong> drugs</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Ubrogepant (Ubrelvy) Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> with at least <strong>one preferred</strong> oral CGRP antagonist </li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>QL</strong> - Nurtec ODT: 8 doses per 30 days for <strong>acute</strong> treatment</p>
<p>Central Nervous System Agents: <strong>Anti-Migraine Agents, Cluster Headache</strong></p>
<p><strong>Length of Authorizations</strong>: 180 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>60 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>An inadequate clinical response to verapamil is defined as a titration to at least 480mg daily</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>QL</strong> - Emgality: 3 doses per 30 days</p>
<p>Central Nervous System Agents: <strong>Anti-Migraine Agents, Prophylaxis</strong></p>
<p><strong>Length of Authorizations</strong>: Initial: 180 days; Subsequent: 365 days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Step Therapy Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>three preferred</strong> controller migraine drugs</li>
<li>Must include objective documentation of severity, frequency, type of migraine, and number of headache days per month (preferably a headache diary)</li>
</ul>
<p><strong>Erenumab (Aimovig) Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>60 days</strong> with the 70mg dose to request a dose increase </li>
</ul>
<p><strong>Fremanezumab (Ajovy) Criteria</strong>:</p>
<ul>
<li>Must have demonstrated efficacy for at least <strong>90 days</strong> before quarterly administration will be authorized</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>three preferred</strong> controller migraine drugs <strong>AND one step therapy</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>Controller migraine drug classes include beta-blockers, anticonvulsants, tricyclic antidepressants, or serotonin-norepinephrine reuptake inhibitors </li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>QL</strong> - Nurtec ODT: 18 doses per 30 days for <strong>prophylactic</strong> treatment</p>
<p><strong>QL</strong> - Aimovig, Ajovy: 1 dose per 30 days</p>
<p><strong>QL</strong> - Emgality: 2 doses per 30 days (for intitial loading dose only), then 1 dose per 30 days thereafter</p>
<p>Central Nervous System Agents: <strong>Anticonvulsants</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days except Epidiolex and Diacomit - Initial: 180 days</p>
<p><strong>Neurologist Exemption</strong></p>
<p>Prescriptions submitted from a prescriber who is credentialed as a neurology specialty with Ohio Medicaid AND for drugs that are used only for
seizures, there must have been an inadequate clinical response of at least <ins>30 days</ins> with <ins>one preferred</ins> drug. This provision applies only to the standard tablet/capsule dosage form.</p>
<p><strong>Grandfathering* (except Diacomit)</strong>:</p>
<p>Patients who have a claim for a non-preferred drug in the previous 120 days will be automatically approved to continue the drug. Patients who have taken the drug previously, but do not have claims history (e.g. new to Medicaid), will need to submit a prior authorization in order to continue coverage.</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Step Therapy Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>one
preferred</strong> drug</li>
</ul>
<p><strong>Cannabidiol (Epidiolex) Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with any two of the following anticonvulsants: clobazam, levetiracetam, valproic acid, lamotrigine, topiramate, rufinamide, or felbamate within the past <strong>365 days</strong> (members who meet this criteria will not require a PA)</li>
</ul>
<p><strong>Stiripentol (Diacomit) Criteria</strong>:</p>
<ul>
<li>Must be prescribed by or in consultation with a neurologist</li>
<li>Must be concomitantly taking clobazam (Onfi)</li>
<li>Must provide documentation of addressed comorbidities and baseline hematologic testing (CBC)<ul>
<li>Patients with phenylketonuria (PKU) must provide evidence of total daily amount of phenylalanine</li>
<li>Prescribers must include management plans for patients with neutrophil counts &lt;1,500 cells/mm3 or platelet count &lt;150,000/µL</li>
</ul>
</li>
<li>Must provide documentation of patient’s weight<ul>
<li>Maximum daily dose does not exceed: 50 mg / kg / day or 3,000 mg / day</li>
</ul>
</li>
<li>Must provide baseline average number of seizure days per month (measured monthly
or quarterly)</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>AR</strong> - Vigabatrin Powder: a PA is required for patients 3 years and older</p>
<p><strong>AR</strong> - Eprontia Solution: a PA is required for patients 12 years and older</p>
<p>Central Nervous System Agents: <strong>Anticonvulsants Rescue</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>AR</strong> - Valtoco: a PA is required for patients younger than 6 years old</p>
<p><strong>AR</strong> - Nayzilam: a PA is required for patients younger than 12 years old</p>
<p>Central Nervous Systems Agents: <strong>Antidepressants</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>Grandfathering</strong>*:</p>
<p>Patients who have a claim for a non-preferred drug, in the previous 120 days will be automatically approved to continue the drug. Patients who have taken the drug previously but do not have claims history (e.g. new to Medicaid), will need to submit a prior authorization in order to continue coverage.</p>
<p><strong>Psychiatrist Exemption</strong>:</p>
<p>Prescribers (as identified below) are exempt from prior authorization of any non-preferred antidepressant, or step therapy of any preferred drug, in the standard tablet/capsule dosage forms. Other dosage forms may still require prior authorization. The exemption will be processed by the claims system when the pharmacy has submitted the prescriber on the claim using the individual national provider identifier (NPI) for the prescriber.</p>
<p>Prescribers are defined as:</br>
Physicians with a specialty in psychiatry, nurse practitioners certified in psychiatric mental health,
or clinical nurse specialists certified in psychiatric mental health, who are credentialed with the Ohio Department of Medicaid.</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>ADDTIONAL DEXTROMETHORPHAN/BUPROPION (AUVELITY) CRITERIA</strong></p>
<ul>
<li>Must have an inadequate clinical response of at least <strong>30 days</strong> with <strong>ALL</strong> of the following:<ul>
<li><strong>ONE</strong> dopamine/norepinephrine reuptake inhibitor (DNRI)</li>
<li><strong>ONE</strong> selective norepinephrine reuptake inhibitor (SNRI)</li>
<li><strong>TWO</strong> selective serotonin reuptake inhibitors (SSRIs) (<strong>ONE</strong> of which must be either vilazodone (Viibryd) or vortioxetine (Trintellix))</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Central Nervous System Agents: <strong>Attention Hyperactivity Disorder Agents</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Step Therapy Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with atomoxetine <strong>OR</strong> at least <strong>two preferred</strong> stimulants</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>three preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>Requests for non-preferred immediate-release formulations must have all required trials with preferred immediate-release drugs, and requests for non-preferred extended-release formulations must have all required trials with preferred extended-release drugs</li>
<li>For patients established on drugs that change from preferred to non-preferred on January 1, a prior authorization is <strong>NOT</strong> required until <strong>after</strong> June 30th of that year.</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>AR</strong> - Adderall, Dexedrine, &amp; Zenzedi IR: a PA is required for patients younger than 3 years
<strong>AR</strong> - Adderall XR, Atomoxetine, Cotempla XR-ODT, Daytrana, Dexedrine ER, Dexmethylphenidate &amp; Methylphenidate IR &amp; ER &amp; Xelstrym: a PA is required for patients younger than 6 years
<strong>AR</strong> - Dextroamphetamine Solution &amp; Dyanavel XR: a PA is required for patients 12 years and older
<strong>AR</strong> - Methylphenidate solutions / suspension: a PA is required for patients younger than 6 years and 12 years and older</p>
<p><strong>Additional Auvelity Criteria</strong>:</p>
<p>-Must have an inadequate clinical response of at least 30 days with <strong>ALL</strong> of the following: 
   - <strong>ONE</strong> dopamine/norepinephrine reuptake inhibitor (DNRI)
   - <strong>ONE</strong> selective norepinephrine reuptake inhibitor (SNRI)
   - <strong>TWO</strong> selective serotonin reuptake inhibitors (SSRIs)(ONE of which must be either vilazodone (Viibryd) OR vortioxetine (Trintellix)</p>
<p>Central Nervous System Agents: <strong>Atypical Antipsychotics</strong>*</p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>Grandfathering</strong>*</p>
<p>Patients who have a claim for a non-preferred drug, or drug requiring step therapy, in the previous 120 days will be automatically approved to continue the drug. Patients who have taken the drug in the previously, but do not have claims history (e.g. new to Medicaid), will need to submit a prior authorization in order to continue coverage.</p>
<p><strong>Psychiatrist Exemption</strong>:</p>
<p>Providers (as identified below) are exempt from prior authorization of any non-preferred second-generation antipsychotic, or step therapy of any preferred drug, in the standard tablet/capsule and long-acting injectable dosage forms. Other dosage forms may still require prior authorization. The exemption will be processed by the claims system when the pharmacy has submitted the prescriber on the claim using the individual national provider identifier (NPI) for the provider.</p>
<p>Prescribers are defined as: </br>
Physicians with a specialty in psychiatry, nurse practitioners certified in psychiatric mental health,
or clinical nurse specialists certified in psychiatric mental health, who are credentialed with the Ohio Department of Medicaid.</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Paliperidone Palmitate (Invega Hafyera) Criteria</strong>:</p>
<ul>
<li>Must have had 4 months of treatment with Invega Sustenna or 3 months with Invega Trinza</li>
</ul>
<p><strong>Step Therapy Approval Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>one preferred</strong> drug</li>
</ul>
<p><strong>Non-Preferred Criteria</strong></p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Aripiprazole (Abilify Mycite) Criteria</strong>:</p>
<ul>
<li>Must be prescribed by or in consultation with a psychiatrist following an aripiprazole serum blood level draw indicating need for further investigation of adherence</li>
</ul>
<p><strong>Additonal Olanzapine / Samidorphan (Lybalvi) Criteria</strong>:</p>
<ul>
<li>Must provide documentation that patient is not using opioids or undergoing acute opioid withdrawal</li>
</ul>
<p><strong>Additional Pimavanserin (Nuplazid) Criteria</strong>:</p>
<ul>
<li>For Parkinson-related Hallucinations &amp; Delusions ALL of the following must be met:</li>
<li>Psychotic symptoms are severe and frequent enough to warrant treatment with an antipsychotic AND are not related to dementia or delirium</li>
<li>The patient’s other Parkinson’s Disease drugs have been reduced or adjusted and psychotic symptoms persist OR patient is unable to tolerate adjustment of these other drugs</li>
<li>Must have been inadequate clinical response or contraindication to at least 30 days of either quetiapine or clozapine</li>
<li>An exemption to the criteria will be authorized for prescribers with a neurology specialty to a patient with a history of the related condition</li>
</ul>
<p><strong>Additional Fluoxetine / Olanzapine (Symbyax) Criteria</strong>:</p>
<ul>
<li>
<p>Must provide documentation for patient’s inability to use the individual drugs
**
Additional Information**:</p>
</li>
<li>
<p>Long-acting injectable antipsychotics may be billed by the pharmacy if they are not dispensed directly to the patient. If not administered by the pharmacist, the drug must be released only to the administering provider or administering provider’s staff, following all regulations for a Prescription Pick-Up Station as described by the Ohio Board of Pharmacy
**
Subsequent Authorization Criteria**:</p>
</li>
<li>
<p>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</p>
</li>
</ul>
<p>Central Nervous System Agents: <strong>Fibromyalgia Agents</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>Drugs and drug classes include gabapentin, pregabalin, short- and/or long-acting opioids, skeletal muscle relaxants, SNRIs, SSRIs, trazodone, and tricyclic antidepressants</li>
<li>The P&amp;T Committee does not recommend the use of opioids for treatment of fibromyalgia</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Central Nervous System Agents: <strong>Medication Assisted Treatment of Opioid Addiction</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Lofexidine (Lucemyra) Criteria</strong></p>
<ul>
<li>May be authorized if ALL of the following criteria are met:</li>
<li>Must provide medical justification supporting why an opioid taper (such as with buprenorphine or methadone) cannot be used</li>
<li>Must have had an inadequate clinical response or contraindication to clonidine</li>
<li>Must provide documentation that the drug was initiated in an inpatient setting to be exempt from the above criteria</li>
</ul>
<p><strong>Buprenorphine Safety Edits and Drug Utilization Review Criteria</strong></p>
<ul>
<li>Prescribing for buprenorphine products must follow the requirements of Ohio Administrative Code rule 4731-33-03 Office based treatment for opioid addiction.</li>
<li>In favor of eliminating prior authorization for all forms of oral short acting buprenorphine- containing products, ODM and the Managed Care Plans will implement safety edits and a retrospective drug utilization review processfor all brand and generic forms of oral short acting buprenorphine-containing products. Safety edits are in place for dosages over 24mg of buprenorphine equivalents/day.</li>
<li>Buprenorphine sublingual tablets (generic Subutex) will be restricted to pregnancy, breastfeeding, or contraindication to preferred products</li>
<li>Buprenorphine injection (Sublocade) dosing schedule will be limited to 300mg/30 days</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>Vivitrol and Sublocade may be billed by the pharmacy if it is not dispensed directly to the patient. If not administered by the pharmacist, the drug must be released only to the administering provider or administering provider's staff, following all regulationsfor a Prescription Pick-Up Station as described by the Ohio Board of Pharmacy.</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Central Nervous System Agents: <strong>Movement Disorders</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Clinical PA Criteria</strong>:</p>
<ul>
<li>Must be prescribed by or in consultation with a neurologist or psychiatrist</li>
</ul>
<p><strong>Step Therapy Approval Criteria</strong>:</p>
<p>Must have an inadequate clinical response of at least <strong>90 days</strong> to a maximally
tolerated dose of tetrabenazine for Huntington’s Disease only</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Central Nervous System Agents: <strong>Multiple Sclerosis</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>Grandfathering</strong>*:</p>
<p>Patients who have a claim for a non-preferred drug in the previous 120 days will be automatically approved to continue the drug. Patients who have taken the drug previously but do not have claims history (e.g. new to Medicaid), will need to submit a prior authorization in order to continue coverage.</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Siponimod (Mayzent) Criteria</strong>:</p>
<ul>
<li>Must provide documentation of genotype, liver function tests (LFTS) complete blood
count (CBC), ophthalmic examination, varicella zoster virus antibodies, and
electrocardiogram (ECG) </li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Central Nervous System Agents: <strong>Narcolepsy</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Oxybate Salts (Xywav) Criteria</strong>:</p>
<ul>
<li>Must have documented adherence to sodium restricted diet</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>AR</strong> - Adderall IR; a PA is required for patients younger than 3 years</p>
<p><strong>AR</strong> - Adderall XR, Dexedrine ER: a PA is required for patients younger than 6 years</p>
<p><strong>AR</strong> - Methylphenidate: a PA is required for patients younger than 6 years</p>
<p>Central Nervous System Agents: <strong>Neuropathic Pain</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Central Nervous System Agents: <strong>Parkinson's Agent</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Apomorphine (Apokin/Kynmobi), Levodopa Inhalation (Inbrija), &amp; Istradefylline (Nourianz) Criteria</strong>:</p>
<ul>
<li>Must have had inadequate clinical response to at least 30 days with one other drug for the treatment of “off episodes” (dopamine agonist, COMT inhibitor, or MAO-B inhibitor)</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Central Nervous System Agents: <strong>Restless Legs Syndrome</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Central Nervous Systems Agents: <strong>Sedative-Hypnotics, Non-Barbiturate</strong></p>
<p><strong>Length of Authorizations</strong>: 180 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>10 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>Non-controlled medications may be authorized if the prescriber indicates the patient has a history of addiction</li>
<li>The P&amp;T Committee does not recommend the use of flurazepam (Dalmane) or triazolam (Halcion)</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Central Nervous System Agents: <strong>Skeletal Muscle Relaxants, Non-Benzodiazepine</strong>:</p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics, requests must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Baclofen Solution Criteria</strong>:</p>
<ul>
<li>Must provide documentation of trial with baclofen tablets or justification why a non-solid oral dosage form is indicated</li>
</ul>
<p><strong>Additional Carisoprodol (Soma) Criteria</strong>:</p>
<ul>
<li>Must provide medical justification that no other muscle relaxant or agent to treat fibromyalgia, or any musculoskeletal condition, would serve the clinical needs of the patient</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient’s clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Central Nervous System Agents: <strong>Smoking Deterrents</strong></p>
<p>All products are covered without a PA</p>
<h2 id="dermatologic_agents">Dermatologic Agents<a class="headerlink" href="#dermatologic_agents" title="Permanent link">&para;</a></h2>
<p>Dermatologic Agents: <strong>Oral Acne Products</strong></p>
<p><strong>Length of Authorizations</strong>: 150 days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Clinical PA Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least 90 days with at least <strong>one preferred</strong> topical <strong>AND one preferred</strong> oral antibiotic for acne</li>
<li>Must be absent of oral tretinoin in the past 56 days</li>
<li>Patient must be registered and meet all of the requirements of the iPLEDGE program</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>90 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>Authorization length will be for no more than 150 days at a time then must take 56
days off</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Dermatologic Agents: <strong>Topical Acne Products</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> (or <strong>90 days</strong> for retinoids) of at least <strong>three preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Tretinoin/Benzoyl Peroxide (Twyneo) Criteria</strong>:</p>
<ul>
<li>Must provide documentation for patient’s inability to use the individual drugs</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>All retinoids – May be authorized with a diagnosis of skin cancer</li>
<li>Tazarotene (Tazorac) – May be authorized with a diagnosis or psoriasis</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient’s clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>AR</strong> - All topical retinoids: a PA is required for patients 24 years and older</p>
<h2 id="endocrine_agents">Endocrine Agents<a class="headerlink" href="#endocrine_agents" title="Permanent link">&para;</a></h2>
<p>Endocrine Agents: <strong>Androgens</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Clinical PA Criteria</strong>:</p>
<ul>
<li>Must provide documentation of lab work to support the need for testosterone supplementation</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred dug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>90 days</strong> with <strong>all preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient’s clinical response to treatment and ongoing safety monitoring (i.e., testosterone and hematocrit)</li>
</ul>
<p><strong>AR</strong> - All drugs: a PA is required for patients younger than 18 years</p>
<p>Endocrine Agents: <strong>Diabetes - Hypoglycemia Treatments</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>two preferred</strong> drugs <strong>OR</strong> the inability of the member and/or caregiver to administer a preferred glucagon product in a timely fashion<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>QL</strong> - All glucagon products: 2 doses per 34 days</p>
<p>Endocrine Agents: <strong>Diabetes Insulin</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Step Therapy Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>120 days</strong> with at least <strong>one
preferred</strong> drug having a similar duration of action </li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>120 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Inhaled Insulin (Afrezza) Criteria</strong>:</p>
<ul>
<li>Must provide documentation of spirometry testing prior to initiation with a predicted FEV1 ≥70% - Will not be authorized for patients with asthma or COPD</li>
<li>Must provide documentation of being nicotine-free for at least 180 days</li>
</ul>
<p><strong>Additional Tempo Pen Criteria</strong></p>
<ul>
<li>Must have had an inadequate clinical response or documentation of medical necessity beyond convenience for why the patient cannot use the corresponding FlexPens or Kwikpens</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>An inadequate clinical response is defined as the inability to reach A1C goal after at least 120 days of current regimen with documented adherence and appropriate dose escalation.</li>
<li>Requests may be authorized for patients with a condition that is difficult to control (i.e., prone to ketoacidosis, hypoglycemia)</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Endocrine Agents: <strong>Diabetes - Non-Insulin</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preffered Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>120 days</strong> with at least <strong>three preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Oral and Injectable Combination Drugs Criteria</strong>:</p>
<ul>
<li>Must have had a trial of at least <strong>120 days</strong> with the individual drugs <strong>OR</strong> must provide
documentation of medical necessity beyond convenience for patient’s inability to use
the individual drugs</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>An inadequate clinical response is defined as the inability to reach A1C goal after at least 120 days of current regimen with documented adherence and appropriate dose escalation.</li>
<li>Requests may be authorized for patients with a condition that is difficult to control (i.e., prone to ketoacidosis, hypoglycemia)</li>
<li>For non-preferred drugs that have preferred drugs in the same drug class: must provide documentation that there was at least one inadequate clinical response with a drug in same drug class</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Endocrine Agents: <strong>Endometriosis</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Step Therapy Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>84 days</strong> with at least <strong>one preferred</strong> NSAID and <strong>one preferred</strong> oral contraceptive </li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>84 days</strong> with at least <strong>one preferred</strong> NSAID, <strong>one preferred</strong> oral contraceptive, AND <strong>one preferred</strong> step-therapy drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Endocrine Agents: <strong>Estrogenic Agents</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>Requests for non-preferred drugs must have an inadequate clinical response with preferred drugs with the same delivery method</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Endocrine Agents: <strong>Growth Hormone</strong></p>
<p><strong>Length of Authorizations</strong>: Initial: 180 days; Subsequent: 365 days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Clincial PA Criteria</strong>:</p>
<p><strong>Pediatric Approvals (under 18 years of age)</strong>:</p>
<ul>
<li>Must be treated and followed by a pediatric endocrinologist, nephrologist, clinical geneticist, endocrinologist, or gastroenterologist (or as appropriate for diagnosis)</li>
<li>Must provide documentation to justify criteria being met, including height, weight, bone age (children), date and results of most current x-ray, stimulus test results, IGF-1 levels, and a growth chart (children)</li>
<li>Must not being used in combination with another somatropin agent</li>
</ul>
<p><strong>Adult Approvals (18 years of age or older)</strong>:</p>
<ul>
<li>Must be treated and following by an endocrinologist</li>
<li>Must provide documentation of growth hormone deficiency by means of a negative response to an appropriate stimulation test (clonidine test is not acceptable for adults)</li>
<li>Must provide documentation of baseline evaluation of the following clinical indicators: (1) insulin-like growth factor (IGF-1); (2) fasting lipid profile; (3) BUN; (4) fasting glucose; (5) electrolytic levels; (6) evaluation of any new osteoarthritis and joint pain; (7) bone density test</li>
<li>Must have had other hormonal deficiencies addressed with adequate replacement therapy</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>90 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient’s clinical response to treatment and ongoingcsafety monitoring (i.e., height, weight gain, improved body composition) For adults: must provide documentation by endocrinologist that discontinuing agent would have a detrimental effect on body composition or other metabolic parameters</li>
</ul>
<p>Endocrine Agents: <strong>Osteoporosis - Bone Ossification Enhancers</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>365 days</strong> with at least <strong>one preferred</strong> drug within the same drug class<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Abaloparatide (Tymlos <sup>TM</sup>) Criteria</strong>:</p>
<p>Must have had an inadequate clinical response of at least <strong>365 days</strong> with <strong>one</strong> bisphosphonate</p>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>Patients should only be on ONE of the therapeutic classes (bisphosphonates, calcitonin-salmon)</li>
<li>A total lifetime duration of therapy of 730 days with any parathyroid analog will be authorized</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Endocrine Agents: <strong>Progestin Agents</strong></p>
<p>All products are covered without a PA</p>
<p>Endocrine Agents: <strong>Uterine Fibroids</strong></p>
<p><strong>Length of Authorizations</strong>: Up to 180 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Clinical PA Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>90 days</strong> with at least one <strong>preferred</strong> oral contraceptive</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>90 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>A total lifetime duration of therapy of 730 days between Oriahnn and Myfembree or 180 days for Lupron Depot will be authorized</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<h2 id="gastrointestinal_agents">Gastrointestinal Agents<a class="headerlink" href="#gastrointestinal_agents" title="Permanent link">&para;</a></h2>
<p>Gastrointestinal Agents: <strong>Anti-Emetics</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>7 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Gastrointestinal Agents: <strong>Crohn's Disease</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days; Ortikos ER - based on indication</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Gastrointestinal Agents: <strong>Hepatic Encephalopathy</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Step Therapy Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> with at least <strong>one</strong>
preferred drug</li>
</ul>
<p><strong>Rifaxamin (Xifaxan) Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> to lactulose to be authorized for monotherapy or add on therapy</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Gastrointestinal Agents: <strong>Irritable Bowel Syndrome (IBS) with Diarrhea</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Step Therapy Approval Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>one
preferred</strong> drug</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Gastrointestinal Agents: <strong>Pancreatic Enzymes</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Gastrointestinal Agents: <strong>Proton Pump Inhibitors</strong></p>
<p><strong>Length of Authorizations</strong>: 180 days, except as listed under additional criteria</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Criteria for PPI Doses Greater than Once Daily</strong>:</p>
<ul>
<li>For H. Pylori diagnosis: Must provide documentation of diagnosis<ul>
<li>Authorization length: 30 days</li>
</ul>
</li>
<li>For any of the following diagnoses: carcinoma of GI tract, COPD, Crest Syndrome, dyspepsia, esophageal varices, gastritis, gastroparesis, scleroderma, symptomatic uncomplicated Barret’s Esophagus, systemic mastocytosis, or Zollinger Ellison Syndrome: Must provide documentation of diagnosis <strong>AND</strong> must have failed once-daily dosing of the requested drug<ul>
<li>Authorization length: 365 days</li>
</ul>
</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>Request may be authorized If the drug was initiated in the hospital for the treatment of a condition such as a GI bleed or the presence of a gastrostomy and/or jejunostomy (G, GJ, J-tube)</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>AR</strong> - Protonix Pak/Pantoprazole Packet: a PA is required for patients 6 years and older</p>
<p><strong>AR</strong> - Omeprazole &amp; Pantoprazole Tab/Cap/ODT: a PA is required for patient 22 years and older requesting more than once daily dosing</p>
<p>Gastrointestinal Agents: <strong>Ulcerative Colitis</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days; except Uceris foam - based on indication</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>QL</strong> - Budesonide ER 9 MG tablets: 56 tablets per 90 days</p>
<p>Gastrointestinal Agents: <strong>Unspecified GI</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days except 3 days for Aemcolo</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Step Therapy Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response to at least <strong>14 days</strong> with at least <strong>two</strong> preferred drugs</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> with at least <strong>three preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Methylnaltrexone (Relistor) and Naldemedine (Symproic) Criteria</strong>:</p>
<ul>
<li>Must have a history of chronic pain requiring continuous opioid therapy for ≥84 days</li>
</ul>
<p><strong>Additional Rifamycin Delayed-Release (Aemcolo) Criteria</strong>:</p>
<p>Must have the inability to take, or failure of <strong>ALL</strong> of the following: azithromycin,
ciprofloxacin, levofloxacin, ofloxacin, or rifaximin</p>
<p><strong>Additional Somatropin Injection (Zorbtive) and Tedloglutide (Gattex) Criteria</strong>:</p>
<ul>
<li>Must have evidence of specialized parenteral nutritional support</li>
<li>Must have documentation of appropriate lab assessment (bilirubin, alkaline phosphatase, lipase, and amylase) at least 180 days prior to initiation</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<h2 id="genitourinary_agents">Genitourinary Agents<a class="headerlink" href="#genitourinary_agents" title="Permanent link">&para;</a></h2>
<p>Genitourinary Agents: <strong>Benign Prostatic Hyperplasia</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Dutasteride / Tamsulosin (Jalyn) Criteria</strong>:</p>
<ul>
<li>Must provide documentation for patient’s inability to use the individual drugs</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Genitourinary Agents: <strong>Electrolyte Depleter Agents</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>7 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Genitourinary Agents: <strong>Urinary Antispasmodics</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drugs with different active ingredients<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>AR</strong> - Vesicare LS: a PA is required for patients younger than 2 years old AND 5 years and older</p>
<p><strong>AR</strong> - Myrbetriq Granules: a PA is required for patients younger than 3 years old AND 5 years and older</p>
<h2 id="immunomodulator_agents">Immunomodulator Agents<a class="headerlink" href="#immunomodulator_agents" title="Permanent link">&para;</a></h2>
<p>Immunomodulator Agents: <strong>Systemic Inflammatory Disease</strong></p>
<p><strong>Length of Authorizations</strong>: Initial: 90 days; Subsequent: 365 days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Clinical PA Criteria</strong>:</p>
<ul>
<li>Must have been an inadequate clinical response of at least <strong>90 days</strong> with at least <strong>two applicable</strong> first-line drugs indicated for diagnosis – provide documentation of the trialed drugs, dosages, dates, and durations</li>
<li>Authorization of dosing regimens (loading/maintenance) will be based upon diagnosis. Document the requested loading and maintenance dosing on PA form, if applicable</li>
<li>Must not have a current, active infection</li>
<li>Must provide evidence of negative TB test prior to initiation of biologic therapy, if required by labeling</li>
</ul>
<p><strong>Step Therapy Approval Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>90 days</strong> with at least <strong>one preferred</strong> TNF inhibitor indicated for diagnosis.</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>90 days</strong> with at least <strong>two preferred</strong> drugs, if indicated for diagnosis<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Atopic Dermatitis Criteria</strong>:</p>
<ul>
<li>Must be prescribed by or in consultation with a dermatologist or allergist/immunologist</li>
<li>Must have at least 10% body surface area (BSA) involvement with <strong>two</strong> of the following: topical corticosteroids, topical calcineurin inhibitors [e.g. Elidel], or topical PDE-4 inhibitors [e.g. Eucrisa] OR atopic dermatitis severe and involves &gt;25% BSA</li>
</ul>
<p><strong>Additional Plaque Psoriasis Criteria</strong>:</p>
<ul>
<li>For patients currently receiving phototherapy, an inadequate clinical response of at least <strong>90 days</strong> must be shown prior to initial authorization for preferred drugs</li>
</ul>
<p><strong>Additional Ulcerative Colitis Criteria</strong>:</p>
<ul>
<li>If an inadequate clinical response after <strong>90 days</strong> with one TNF inhibitor, further TNF inhibitors will not be authorized</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient’s clinical response to treatment and ongoing safety monitoring</li>
</ul>
<h2 id="infectious_disease_agents">Infectious Disease Agents<a class="headerlink" href="#infectious_disease_agents" title="Permanent link">&para;</a></h2>
<p>Infectious Disease Agents: <strong>Antibiotics - Cephalosporins</strong></p>
<p><strong>Length of Authorizations</strong>: Based on indication</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>3 days</strong> with at least <strong>one preferred</strong> antibiotic<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>Requests may be authorized if:<ul>
<li>The infection is caused by an organism resistant to ALL preferred antibiotics (must provide diagnosis and any culture/sensitivity results)</li>
<li>The patient is completing a course of therapy that was started in the hospital or other similar location or was started before Medicaid eligibility, only the remaining course will be authorized</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring, <strong>AND</strong> medical necessity for continued use</li>
</ul>
<p><strong>AR</strong> - Cefaclor Suspension: a PA is required for patients 12 years and older</p>
<p><strong>AR</strong> - Cefixime Suspension: a PA is required for patients 12 years and older</p>
<p><strong>AR</strong> - Cefprozil Suspension: a PA is required for patients 12 years and older</p>
<p><strong>AR</strong> - Suprax Chewable Tablet: a PA is required for patients 12 years and older</p>
<p>Infectious Disease Agents: <strong>Antibiotics - Inhaled</strong></p>
<p><strong>Length of Authorizations</strong>: Initial: 180 days; Subsequent 365 days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Clinical PA Criteria</strong>:</p>
<ul>
<li>Must provide documentation of cultures demonstrating drug is prescribed in alignment with approved indication</li>
</ul>
<p><strong>Non-Preferreed Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>28 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring (i.e., culture conversion, symptom improvement)</li>
</ul>
<p><strong>QL</strong> - Tobramycin drugs: 56 doses in 56 days</p>
<p>Infectious Disease Agents: <strong>Antibiotics - Macrolides</strong></p>
<p><strong>Length of Authorizations</strong>: Based on indication</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>3 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>Requests may be authorized if:<ul>
<li>The infection is caused by an organism resistant to ALL preferred antibiotics (must provide diagnosis and any culture/sensitivity results)</li>
<li>The patient is completing a course of therapy that was started in the hospital or other similar location or was started before Medicaid eligibility, only the remaining course will be authorized</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring, <strong>AND</strong> medical necessity for continued use</li>
</ul>
<p>Infectious Disease Agents: <strong>Antibiotics - Quinolones</strong></p>
<p><strong>Length of Authorizations</strong>: Based on indication</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>3 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>Requests may be authorized if:<ul>
<li>The infection is caused by an organism resistant to ALL preferred antibiotics (must provide diagnosis and any culture/sensitivity results)</li>
<li>The patient is completing a course of therapy that was started in the hospital or other similar location or was started before Medicaid eligibility, only the remaining course will be authorized</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring, <strong>AND</strong> medical necessity for continued use</li>
</ul>
<p><strong>AR</strong> - Ciprofloxacin Suspension: a PA is required for patients 12 years and older</p>
<p>Infectious Disease Agents: <strong>Antibiotics - Tetracyclines</strong></p>
<p><strong>Length of Authorizations</strong>: Based on indication for acute infections or 365 days for acne</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>3 days</strong> with at least <strong>one preferred</strong> drug for acute infections <strong>OR</strong> at least <strong>90 days</strong> with at least <strong>one preferred oral</strong> drug for acne<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>Requests may be authorized if:<ul>
<li>The infection is caused by an organism resistant to ALL preferred antibiotics (must provide diagnosis and any culture/sensitivity results)</li>
<li>The patient is completing a course of therapy that was started in the hospital or other similar location or was started before Medicaid eligibility, only the remaining course will be authorized</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring, <strong>AND</strong> medical necessity for continued use</li>
</ul>
<p><strong>AR</strong> - Vibramycin Suspension: a PA is required for patients 12 years and older </p>
<p><strong>AR</strong> - Doxycycline Syrup: a PA is required for patients 12 years and older</p>
<p>Infectious Disease Agents: <strong>Antifungals</strong></p>
<p><strong>Length of Authorizations</strong>: Based on indication</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>7 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Oteseconazole (Vivjoa) Criteria</strong>:</p>
<ul>
<li>Must provide documentation of at least three symptomatic episodes of vulvovaginal candidiasis in the past 12 months</li>
<li>Must provide documentation of non-reproductive potential (i.e, post-menopausal)</li>
<li>Must have had an inadequate clinical response of at least <strong>180 day</strong> maintenance course with oral fluconazole shown by documentation of more than <strong>one</strong> breakthrough infection </li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>Requests may be authorized if:<ul>
<li>The infection is caused by an organism resistant to <strong>ALL</strong> preferred antifungals (must provide diagnosis and any culture/sensitivity results)</li>
<li>The patient is completing a course of therapy that was started in the hospital or other similar location or was started before Medicaid eligibility, only the remaining course will be authorized</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring, <strong>AND</strong> medical necessity for continued use</li>
</ul>
<p>Infectious Disease Agents: <strong>Antivirals - Hepatitis C Agents</strong></p>
<p><strong>Length of Authorizations</strong>: Dependent upon authorized course</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Clinical PA Criteria</strong></p>
<ul>
<li>Only regimens recommended by the American Association for the Study of Liver Diseases (AASLD) will be authorized</li>
<li>Please see the <a :target="_blank" href="https://pharmacy.medicaid.ohio.gov/sites/default/files/HepC_PA_Form_20211119.pdf#overlay-context=prior-authorization" rel="noopener">Hepatitis C Direct Acting Antiviral Prior Authorization Form</a> for criteria </li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response defined as not achieving SVR with guideline-recommended preferred drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>Requests for patients established on current therapy with prior payer (i.e., Commercial, Fee-for-Service, Managed Care Plan, etc) will be authorized with documentation</li>
<li>Requests for regimens including pegylated Interferons must include close monitoring with periodic clinical and laboratory evaluations</li>
<li>Requests for regimens including ribavirins must include documentation of at least two reliable forms of contraception being used during therapy</li>
</ul>
<p>Infectious Disease Agents: <strong>Antivirals - Herpes</strong></p>
<p><strong>Length of Authorizations</strong>: For the duration of the prescription (up to 180 days)</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>3 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong></p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Infectious Disease Agents: <strong>Antivirals - HIV</strong>*</p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>Grandfathering</strong>*:</p>
<p>Patients who have a claim for a non-preferred drug in the previous 120 days will be automatically approved to continue the drug. Patients who have taken the drug previously, but do not have claims history (e.g. new to Medicaid), will need to submit a prior authorization in order to continue coverage.</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Abacavir/Dolutegravir/Lamivudine (Triumeq PD) Criteria</strong></p>
<ul>
<li>Must provide documentation of patient’s weight (only authorized for those 10 – 25 kg)</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>one preferred</strong> drug. If applicable, the request must address the inability to use the individual components.<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide information of patient’s clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>AR</strong> – Isentress chewable tablet: a PA is required for patients 12 years and older</p>
<p><strong>AR</strong> – Lamivudine solution: a PA is required for patients 3 years and older</p>
<p><strong>AR</strong> – Nevirapine solution: a PA is required for patients 3 years and older</p>
<h2 id="ophthalmic_agents">Ophthalmic Agents<a class="headerlink" href="#ophthalmic_agents" title="Permanent link">&para;</a></h2>
<p>Ophthalmic Agents: <strong>Antibiotic and Antibiotic-Steroid Combination Drops and Ointments</strong></p>
<p><strong>Length of Authorizations</strong>: 30 days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>3 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>Requests may be authorized if:<ul>
<li>The infection is caused by an organism resistant to <strong>ALL</strong> preferred antibiotics (must provide diagnosis and any culture/sensitivity results)</li>
<li>The patient is completing a course of therapy that was started in the hospital or other similar location or was started before Medicaid eligibility, only the remaining course will be authorized</li>
</ul>
</li>
</ul>
<p>Ophthalmic Agents: <strong>Antihistamines &amp; Mast Cell Stabilizers</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Ophthalmic Agents: <strong>Dry Eye Treatments</strong></p>
<p><strong>Length of Authorizations</strong>: 14 Days for Eysuvis; 365 Days for all other agents</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Step Therapy Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> with <strong>one</strong> artificial tear or OTC dry eye drop in the previous 120 days </li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Ophthalmic Agents: <strong>Glaucoma Agents</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Step Therapy Approval Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>one preferred</strong> drug in the same class, if available</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two preferred</strong> drugs in the same class, if available<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Ophthalmic Agents: <strong>NSAIDs</strong></p>
<p><strong>Length of Authorizations</strong>: 30 days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>3 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p>Ophthalmic Agents: <strong>Ophthalmic Steroids</strong></p>
<p><strong>Length of Authorizations</strong>: 30 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>14 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<h2 id="otic_agents">Otic Agents<a class="headerlink" href="#otic_agents" title="Permanent link">&para;</a></h2>
<p>Otic Agents: <strong>Antibacterial and Antibacterial/Steroid Combinations</strong></p>
<p><strong>Length of Authorizations</strong>: 30 days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>7 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<h2 id="respiratory_agents">Respiratory Agents<a class="headerlink" href="#respiratory_agents" title="Permanent link">&para;</a></h2>
<p>Respiratory Agents: <strong>Antihistamines - Second Generation</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two different preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>AR</strong> - Cetirizine Chewables: a PA is required for patients 6 years and older</p>
<p>Respiratory Agents: <strong>Cystic Fibrosis</strong></p>
<p><strong>Length of Authorizations</strong>: Initial 90 days; Subsequent 365 days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Clinical PA Criteria</strong>:</p>
<ul>
<li>Must be prescribed by or in consultation with a pulmonologist or infectious disease specialist</li>
<li>Must provide documentation of the genetic mutation</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Bronchitol Criteria</strong>:</p>
<ul>
<li>Must be used as an add-on maintenance therapy</li>
<li>Must provide documentation of a completed Bronchitol Tolerance Test </li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient’s clinical response to treatment (adherence to
treatment demonstrated by claims history <strong>AND</strong> one or more of the following: FEV1,
weight gain, sweat chloride, pulmonary exacerbations, etc.) and ongoing safety
monitoring</li>
</ul>
<p>Respiratory Agents: <strong>Epinephrine Auto-Injectors</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response to at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Respiratory Agents: <strong>Hereditary Angioedema</strong></p>
<p><strong>Length of Authorizations</strong>: Initial: 90 days; Subsequent: 180 days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Clinical PA Criteria</strong>:</p>
<ul>
<li>Must provide documentation of diagnosis (i.e., C1-INH deficiency or dysfunction (Type I or
II HAE)) and whether the drug will be used for prophylaxis or treatment</li>
<li>Must provide documentation of at-home administration</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response to at least <strong>60 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Respiratory Agents: <strong>Inhaled Agents</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response to at least <strong>14 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Steroid-Containing Inhaler Criteria</strong>:</p>
<ul>
<li>May be authorized if documentation of one of the following is provided:<ul>
<li>Patient is 12 years or younger OR is disabled and is unable to use a preferred inhaler</li>
<li>Patient has been non-compliant on a preferred inhaler due to taste, dry mouth, or infection</li>
<li>Patient is clinically unstable, as defined by current guidelines in terms of oral steroid use or patient’s current symptomatology</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>AR</strong> - Albuterol Nebulizer Solution 0.021% (0.63 MG / 3 ML), 0.042% (1.25 MG / 3 ML): a PA is required for patients 13 years and older </p>
<p><strong>AR</strong> - Budesonide Nebulizer Solution: a PA is required for patients 7 years and older</p>
<p>Respiratory Agents: <strong>Leukotriene Receptor Modifiers &amp; Inhibitors</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Step Therapy Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>90 days</strong> with at least <strong>one preferred</strong> drug</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response to at least <strong>90 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Respiratory Agents: <strong>Monoclonal Antibodies-Anti-IL/Anti-IgE</strong></p>
<p><strong>Length of Authorizations</strong>: Initial: 180 days; Subsequent: 365 days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Clinical PA Criteria</strong>:</p>
<ul>
<li>Must be prescribed by or in consultation with an applicable specialist (i.e., allergist/immunologist, pulmonologist, or otolaryngologist)</li>
<li>For <strong>Asthma</strong> – Must have had uncontrolled asthma symptoms and/or exacerbations despite at least <strong>30 days</strong> with:<ul>
<li>Medium dose preferred ICS/LABA inhaler for 6 years and older <strong>OR</strong> medium dose preferred ICS/LABA inhaler with tiotropium or high dose ICS/LABA inhaler if 12 years and older</li>
</ul>
</li>
<li>For <strong>Chronic Rhinosinusitis with Nasal Polyposis</strong> – Must have had an inadequate clinical response of at least <strong>30 days</strong> to at least <strong>one oral</strong> corticosteroid AND <strong>one nasal</strong> corticosteroid spray</li>
<li>For <strong>Chronic Urticaria</strong> – Must have had an inadequate clinical response to at least <strong>14 days</strong> with at least <strong>two different</strong> antihistamines</li>
</ul>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response of at least <strong>90 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics, requests must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring (i.e., PFT improvement, reduced affected BSA)</li>
</ul>
<p>Respiratory Agents: <strong>Nasal Preparations</strong></p>
<p><strong>Length of Authorizations</strong>: 365 days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response to at least <strong>30 days</strong> with at least <strong>two preferred</strong> drugs in the same class, if available<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Respiratory Agents: <strong>Other Agents</strong></p>
<p><strong>Length of Authorizations</strong>: Initial: 90 days; Subsequent: 180 days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong></p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response to at least <strong>90 days</strong> with at least <strong>one preferred</strong> long-acting beta agonist <strong>AND one preferred</strong> long-acting muscarinic antagonist-containing inhalers<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Roflumilast (Daliresp) Criteria</strong></p>
<ul>
<li>Must be used in addition to a long-acting beta agonist AND a long-acting muscarinic antagonist-containing inhalers </li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment, adherence to maintenance inhaler per pharmacy claims, and ongoing safety monitoring</li>
</ul>
<h2 id="topical_agents">Topical Agents<a class="headerlink" href="#topical_agents" title="Permanent link">&para;</a></h2>
<p>Topical Agents: <strong>Antifungals</strong></p>
<p><strong>Length of Authorizations</strong>: Up to 180 days for all agents except 365 days for Jubila</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response to at least <strong>14 days</strong> with at least <strong>two preferred</strong> drugs, if indicated for diagnosis<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Additional Efinaconazole (Jublia) Criteria</strong>:</p>
<p>Must have had an inadequate clinical response of at least <strong>365 days</strong> with at least <strong>one preferred</strong> topical drug AND at least <strong>84 days</strong> with at least <strong>one preferred</strong> oral drug indicated for diagnosis</p>
<p><strong>Additional Information</strong>:</p>
<ul>
<li>Requests may be authorized if:<ul>
<li>The infection is caused by an organism resistant to preferred antibiotics drugs (note diagnosis and any culture/sensitivity results)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Topical Agents: <strong>Antiparasitics</strong></p>
<p><strong>Length of Authorizations</strong>: 14 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response to at least <strong>14 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Topical Agents: <strong>Corticosteroids</strong></p>
<p><strong>Length of Authorizations</strong>: 365 days for low and medium potency; 90 days for high and very high potency</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Non-Preferred Criteria</strong>:</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response to at least <strong>14 days</strong> with at least <strong>two preferred</strong> drugs<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p>Topical Agents: <strong>Immunomodulators</strong></p>
<p><strong>Length of Authorizations</strong>: 365 Days</p>
<p><strong>All Authorizations</strong>: Must be prescribed in accordance with FDA approved labeling</p>
<p><strong>Step Therapy Approval Criteria</strong>:</p>
<ul>
<li>Must have had an inadequate clinical response of at least <strong>30 days</strong> with at least <strong>two</strong> topical corticosteroids</li>
</ul>
<h3 id="non-preferred">Non-Preferred<a class="headerlink" href="#non-preferred" title="Permanent link">&para;</a></h3>
<p>Non-Preferred Criteria</p>
<ul>
<li>Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) <strong>OR</strong><ul>
<li>For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation</li>
</ul>
</li>
<li>Must have had an inadequate clinical response to at least <strong>30 days</strong> with at least <strong>one preferred</strong> drug<ul>
<li>For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)</li>
<li>For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)</li>
</ul>
</li>
</ul>
<p><strong>Subsequent Authorization Criteria</strong>:</p>
<ul>
<li>Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring</li>
</ul>
<p><strong>AR</strong> - pimecrolimus and tacrolimus: a PA is required for patients younger than 2 years old</p>







  
  






                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    <script id="__config" type="application/json">{"base": "../../..", "features": ["navigation.instant", "navigation.tabs", "navigation.prune", "search.highlight", "content.action.edit"], "search": "../../../assets/javascripts/workers/search.6ce7567c.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}}</script>
    
    
      <script src="../../../assets/javascripts/bundle.56dfad97.min.js"></script>
      
    
  </body>
</html>